MTMR2 Activators
MTMR2 Activators are a diverse group of chemical compounds that indirectly enhance the phosphatase activity of myotubularin-related protein 2 (MTMR2) by modulating the cellular levels of its substrates, the phosphatidylinositol phosphates. These activators accomplish this by inhibiting various enzymes in the phosphoinositide signaling pathways, such as phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), which are responsible for the phosphorylation that converts these phosphates into forms that are not substrates for MTMR2. For example, LY294002 and Wortmannin are both PI3K inhibitors that increase the levels of MTMR2's substrates, thereby enhancing the dephosphorylation activity of MTMR2. Similarly, mTOR inhibitors like Rapamycin and PP242 indirectly increase the activity of MTMR2 by modulating the cellular processes that control the levels of phosphoinositides, which are essential for MTMR2's function.
These MTMR2 Activators, including PI3K inhibitors such as ZSTK474 and PIK-93, as well as mTOR inhibitors like Torin 1, lead to an accumulation of MTMR2 substrates within the cell. This accumulation enhances the natural activity of MTMR2, as it has more substrate to act upon. Moreover, Akt inhibitors like Perifosine reduce the downstream effects of Akt phosphorylation, which can result in increased levels of MTMR2 substrates.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphatidylinositol 3-kinase (PI3K), which when inhibited, can increase the activity of MTMR2 as PI3K negatively regulates the phosphatase function of MTMR2 by altering the levels of phosphoinositides. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor which, by inhibiting mTOR complex 1 (mTORC1), can lead to the activation of MTMR2 due to the complex interplay between mTOR signaling and phosphoinositide levels in the cell. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
Perifosine is an Akt inhibitor, and by inhibiting Akt, it can indirectly enhance MTMR2 activity because Akt activation is generally associated with the phosphorylation of MTMR2 substrates, which MTMR2 then dephosphorylates. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is a selective mTOR kinase inhibitor that, by inhibiting both mTORC1 and mTORC2 complexes, could enhance MTMR2 activity due to reduced phosphorylation of MTMR2's downstream targets, increasing their availability for dephosphorylation. | ||||||
ZSTK 474 | 475110-96-4 | sc-475495 | 5 mg | $75.00 | ||
ZSTK474 is a PI3K inhibitor that could enhance MTMR2 activity by preventing the phosphorylation of phosphoinositides, thus increasing the pool of substrates available for dephosphorylation by MTMR2. | ||||||
PIK-93 | 593960-11-3 | sc-364588 | 5 mg | $255.00 | ||
PIK-93 is a PI4K inhibitor which can indirectly enhance MTMR2 activity by reducing the production of PI4P, a substrate for MTMR2, leading to increased dephosphorylation activity of MTMR2 on other phosphoinositides. | ||||||
Apilimod | 541550-19-0 | sc-480051 sc-480051A | 100 mg 1 g | $428.00 $2652.00 | 5 | |
Apilimod is a selective inhibitor of PIKfyve, which synthesizes PIP2 from PIP; by inhibiting PIKfyve, Apilimod could enhance MTMR2 activity by increasing the relative concentration of MTMR2's substrates. | ||||||
PI 3-Kγ Inhibitor | 648450-29-7 | sc-203191 | 5 mg | $76.00 | ||
AS605240 is a selective PI3Kγ inhibitor that could enhance MTMR2 activity by specifically altering the signaling pathways that rely on PI3Kγ, leading to changes in phosphoinositide levels that MTMR2 can then dephosphorylate. | ||||||
PI 3-Kβ Inhibitor VI, TGX-221 | 663619-89-4 | sc-203190 | 1 mg | $437.00 | ||
TGX-221 is a selective PI3Kβ inhibitor that could enhance MTMR2 activity by inhibiting the PI3Kβ pathway, leading to increased availability of dephosphorylated phosphoinositides, which are substrates for MTMR2. | ||||||